InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at HLTH 2023
Nemaura (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting diabetes management and personalized lifestyle coaching programs. The company today announced that it will be participating at the HLTH 2023 conference, which is taking place in Las Vegas in October. The company’s attendance is in response to several inquiries from existing diabetes and metabolic health program providers, to integrate the daily wear Continuous Glucose Monitor (“CGM”) into existing diabetes care, metabolic health and weight-loss programs. Nemaura believes that its proprietary technology can serve as a powerful complement to program providers, empowering users with access to personalized data, insights and guidance based on their body’s response to glucose intake. The expected result is for users to be able to have conversations with their existing program provider on a broad range of health and weight-loss topics, including asking for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.
To view the full press release, visit https://ibn.fm/12ieb
About Nemaura Medical Inc.
Nemaura is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently also commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines non-invasive glucose data processed using artificial intelligence as part of a lifestyle program that is being refined for commercial launch. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN